Clyra Medical Technologies, Inc.
Developer of wound- and skin-care products based on a copper-iodine oxidative chemistry intended to provide broad-spectrum antimicrobial activity, biofilm control, and biocompatibility. The company develops multiple product formats (liquid irrigation, hydrogels, dressings and pads) for clinical and consumer applications and targets wound care, surgical irrigation, dental/oral care and related markets. Clyra has pursued regulatory clearance for its wound irrigation solution and has integrated GLP and ISO biocompatibility testing into its product development program.
Industries
Nr. of Employees
small (1-50)
Clyra Medical Technologies, Inc.
3802 Spectrum Blvd, Suite 115, Tampa, FL 33612
Patents
Disinfectants with iodine and copper complexes for use against coronavirus
US-11744249-B2
View DetailsDisinfectants with iodine and copper complexes for use against coronavirus
US-11457632-B1
View Details
Disinfectants with iodine and copper complexes for use against coronavirus
US-11744249-B2
View DetailsDisinfectants with iodine and copper complexes for use against coronavirus
US-11457632-B1
View DetailsProducts
Wound irrigation solution (copper-iodine complex) — cleared under FDA 510(k)
A clear, non-irritating wound irrigation formulation based on a copper-iodine complex; indicated for acute and chronic wounds and reported to provide high antimicrobial activity and biofilm reduction with sustained efficacy.
Antimicrobial wound hydrogel (in development)
Hydrogel dressing designed to hydrate and protect acute and chronic wounds while providing antimicrobial activity and odor control.
Super-absorbent pads and antimicrobial dressings (in development)
Highly absorbent pads and dressings impregnated with antimicrobial technology to manage heavy exudate and bodily fluids while providing odor control.
NPWT-compatible irrigation and dressing integration (in development)
Impregnation of antimicrobial technology into dressings for negative pressure wound therapy and use as an irrigation solution compatible with NPWT systems.
Oral rinse for dental hygiene (product under development)
A clear oral rinse based on the copper-iodine complex platform intended for gum health and dental hygiene; described for twice-daily use as a rinse.
Autologous stem-cell-derived wound biogel (acquired technology)
Acquired autologous cell-rich biogel technology intended to support healing of chronic wounds using a patient’s own cells and plasma.
Wound irrigation solution (copper-iodine complex) — cleared under FDA 510(k)
A clear, non-irritating wound irrigation formulation based on a copper-iodine complex; indicated for acute and chronic wounds and reported to provide high antimicrobial activity and biofilm reduction with sustained efficacy.
Antimicrobial wound hydrogel (in development)
Hydrogel dressing designed to hydrate and protect acute and chronic wounds while providing antimicrobial activity and odor control.
Super-absorbent pads and antimicrobial dressings (in development)
Highly absorbent pads and dressings impregnated with antimicrobial technology to manage heavy exudate and bodily fluids while providing odor control.
NPWT-compatible irrigation and dressing integration (in development)
Impregnation of antimicrobial technology into dressings for negative pressure wound therapy and use as an irrigation solution compatible with NPWT systems.
Oral rinse for dental hygiene (product under development)
A clear oral rinse based on the copper-iodine complex platform intended for gum health and dental hygiene; described for twice-daily use as a rinse.
Autologous stem-cell-derived wound biogel (acquired technology)
Acquired autologous cell-rich biogel technology intended to support healing of chronic wounds using a patient’s own cells and plasma.
Services
Design and development of antimicrobial wound-care formulations and devices across multiple formats including liquids, hydrogels and impregnated dressings.
Assistance with FDA 510(k) regulatory pathway, clinical trial planning and access to clinical advisory boards.
Commercial partnership, licensing and go-to-market support for incorporating antimicrobial technology into partner products.
Design and development of antimicrobial wound-care formulations and devices across multiple formats including liquids, hydrogels and impregnated dressings.
Assistance with FDA 510(k) regulatory pathway, clinical trial planning and access to clinical advisory boards.
Commercial partnership, licensing and go-to-market support for incorporating antimicrobial technology into partner products.
Expertise Areas
- Advanced wound care product development
- Antimicrobial formulation and biofilm control
- Preclinical GLP and ISO biocompatibility testing
- Regulatory submissions (FDA 510(k))
Key Technologies
- Copper-iodine complex advanced oxidation chemistry
- Antimicrobial oxidative formulations
- Hydrogel and impregnated dressing technologies
- Biofilm assay and control methods
News & Updates
Announcement of agreements to acquire a stem cell therapy technology (SkinDisc) to be sold through the Clyra subsidiary and plans to integrate Scion Solutions team members into Clyra's commercial strategy.
Press release stating that BioLargo's subsidiary secured over $1 million in new capital and finalized acquisition of the SkinDisc technology.
The company states that its first wound management product has received FDA 510(k) clearance.
Announcement of agreements to acquire a stem cell therapy technology (SkinDisc) to be sold through the Clyra subsidiary and plans to integrate Scion Solutions team members into Clyra's commercial strategy.
Press release stating that BioLargo's subsidiary secured over $1 million in new capital and finalized acquisition of the SkinDisc technology.
The company states that its first wound management product has received FDA 510(k) clearance.